Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

• Published in: Blood Vol. 144; no. Supplement 1; p. 1693
• Main Authors: Ruan, Jia, Orlando, Evelyn H., Moskowitz, Alison, Chen, Zhengming, Mehta-Shah, Neha, Sokol, Lubomir, Horwitz, Steven, Rutherford, Sarah C., Sahni, Tejasvi, Melnick, Ari M, Inghirami, Giorgio, Cerchietti, Leandro, Leonard, John P., Martin, Peter
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 05.11.2024

INTRODUCTION: We previously reported the efficacy including induction response rates (ORR 75% and CR 75%) and early survival outcome (2-yr OS 69% and 2-yr PFS 66%) of an exploratory phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL (ClinicalTrials.gov - NCT03542266;...